Table 2. Clinical features of the participants.

Variables	Males (n=145)			Females (n=52)			Mean difference	95% CI	p
	n	%	Mean±SD	n	%	Mean±SD
Time since first CAD event (month)			15.5±14.8			21.1±16.8	5.627	0.722-10.532	0.025
Ejection fraction (%)			54.7±10.1			56.5±7.1	1.502	-2.220-5.224	0.426
Type of CAD event								0.017-0.024	0.025
CABG/PCI with MI	84	58		19	37
CABG/PCI without MI	37	26		22	42
CAD without MI/CABG/PCI	24	16		11	21
Presence of angina	39	27		26	50			0.077-0.091	0.003
Complications
Atrial fibrillation	7	5		3	6			1.000-1.000	0.725
Ventricular arrhythmia	15	10		4	8			0.429-0.455	0.785
Arrest	4	3		1	2			0.671-0.694	1.000
Mechanical ventilation	1	1		1	2			1.000-1.000	0.459
Medications
Beta blocker	112	79		37	71			0.017-0.024	0.257
ACEI	82	58		40	77			0.243-0.266	0.018
Antiarrhythmic	6	4		3	6			1.000-1.000	0.703
Nitrates	2	1		5	10			0.025-0.034	0.016
Diuretic	52	37		18	35			0.459-0.485	0.867
Lipid lowering	86	61		28	54			0.060-0.073	0.415
Aspirin	96	68		37	71			0.243-0.265	0.728
Clopidogrel	53	37		18	35			0.229-0.251	0.867
Coexisting diseases
HT	74	51		37	71			0.049-0.061	0.014
DM	36	25		30	58			0.001-0.003	<0.001
HPL	76	52		35	67			0.195-0.216	0.074
LBP	37	26		30	58			0.000-0.000	<0.001
OA	11	8		25	48			0.000-0.000	<0.001
COPD	10	7		1	2			0.166-0.185	0.294
Psychiatric dis	2	1		6	12			0.001-0.003	0.005
Smoking	63	43		9	17			0.053-0.066	<0.001
SD: Standard deviation; CI: Confidence interval; CAD: Coronary artery disease; CABG: Coronary artery bypass grafting; PCI: Percutaneous coronary intervention; MI: Myocardial infarction; ACEI: Angiotension converting enzyme inhibitor; HT: Hypertension; DM: Diabetes mellitus; HPL: Hyperlipidemia; LBP: Low back pain; OA: Osteoarthritis; COPD: Chronic obstructive pulmonary disease.